Moleculin Hits 45-Patient Milestone in Key AML Trial, Sets Stage for Mid-2026 Data Unblinding — Moleculin Biotech, Inc.

Event summary

Moleculin Biotech enrolled the 45th patient in its pivotal Phase 2B/3 MIRACLE trial for Annamycin in relapsed/refractory AML.
CEO Walter Klemp highlighted the milestone in a virtual investor segment, noting it triggers final prep for mid-2026 interim data unblinding.
Annamycin is being tested in combination with cytarabine (AnnAraC) for treating adult R/R AML patients.
The trial follows a successful Phase 1B/2 study, with FDA input de-risking the development pathway.

The big picture

Moleculin's progress in the MIRACLE trial represents a critical inflection point for its lead candidate Annamycin, which aims to address the cardiotoxicity limitations of current anthracycline treatments. The company's ability to secure additional financing will be pivotal as it navigates the final stages of this pivotal trial, with broader implications for the competitive landscape in relapsed/refractory AML therapies.

What we're watching

Trial Execution: Whether Moleculin can maintain its aggressive timeline for interim data unblinding amid potential financing constraints.
Regulatory Pathway: How the FDA's evolving feedback may impact the trial's adaptive design and ultimate approval strategy.
Market Differentiation: The pace at which Annamycin's cardiotoxicity-free profile can position it against existing AML treatments.